Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

601

Enrollment

INDUSTRY

Sponsor class

Conditions

CMV Disease

Interventions

DRUG: Letermovir
DRUG: Valganciclovir
DRUG: Acyclovir (ACV)
DRUG: Placebo to ACV
DRUG: Placebo to LET
DRUG: Placebo to VGCV

Sponsor

Merck Sharp & Dohme LLC